{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:34Z","timestamp":1793316334910,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA25224"],"award-info":[{"award-number":["U10 CA25224"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA031946"],"award-info":[{"award-number":["U10 CA031946"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["CI-45-09"],"award-info":[{"award-number":["CI-45-09"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,27]]},"DOI":"10.1093\/neuonc\/nox161","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T15:13:25Z","timestamp":1503328405000},"page":"546-556","source":"Crossref","is-referenced-by-count":135,"title":["Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02"],"prefix":"10.1093","volume":"20","author":[{"given":"Evanthia","family":"Galanis","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Keith","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"},{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Ryan","family":"Miller","sequence":"additional","affiliation":[{"name":"Pathobiology and Translational Science Graduate Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Jaeckle","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Jacksonville, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C","family":"Buckner","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L","family":"Ligon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla V","family":"Ballman","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Dennis F","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cancer Center of Kansas, Wichita, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nebozhyn","sequence":"additional","affiliation":[{"name":"Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Loboda","sequence":"additional","affiliation":[{"name":"Data Analysis, Informatics & Analysis Department, Merck Research Laboratories, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Center, University of Virginia School of Medicine, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet Singh","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J","family":"Lesser","sequence":"additional","affiliation":[{"name":"Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Prados","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medicine & Neurosurgery, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alliance for Clinical Trials in Oncology and ABTC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"key\n\t\t\t\t20180420105421_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20180420105421_CIT0002","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"key\n\t\t\t\t20180420105421_CIT0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"key\n\t\t\t\t20180420105421_CIT0004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"32","key":"key\n\t\t\t\t20180420105421_CIT0005","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t20180420105421_CIT0006","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180420105421_CIT0007","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399411001888","article-title":"Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain","volume":"13","author":"Agarwal","year":"2011","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"key\n\t\t\t\t20180420105421_CIT0008","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s11064-011-0701-1","article-title":"Drug resistance in glioblastoma: a mini review","volume":"37","author":"Haar","year":"2012","journal-title":"Neurochem Res"},{"issue":"10","key":"key\n\t\t\t\t20180420105421_CIT0009","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180420105421_CIT0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","article-title":"Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation","volume":"86","author":"Lehrmann","year":"2002","journal-title":"Adv Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20180420105421_CIT0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: an attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med Res Rev"},{"key":"key\n\t\t\t\t20180420105421_CIT0012","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.biochem.67.1.545","article-title":"Alteration of nucleosome structure as a mechanism of transcriptional regulation","volume":"67","author":"Workman","year":"1998","journal-title":"Annu Rev Biochem"},{"issue":"37","key":"key\n\t\t\t\t20180420105421_CIT0013","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"key\n\t\t\t\t20180420105421_CIT0014","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"key\n\t\t\t\t20180420105421_CIT0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"key\n\t\t\t\t20180420105421_CIT0016","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"key\n\t\t\t\t20180420105421_CIT0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"key\n\t\t\t\t20180420105421_CIT0018","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14728222.9.4.809","article-title":"Histone deacetylase inhibitors: insights into mechanisms of lethality","volume":"9","author":"Rosato","year":"2005","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"key\n\t\t\t\t20180420105421_CIT0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"key\n\t\t\t\t20180420105421_CIT0020","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1471-4159.2005.03098.x","article-title":"Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo","volume":"93","author":"Ey\u00fcpoglu","year":"2005","journal-title":"J Neurochem"},{"issue":"3","key":"key\n\t\t\t\t20180420105421_CIT0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-007-9337-z","article-title":"Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model","volume":"83","author":"Ugur","year":"2007","journal-title":"J Neurooncol"},{"issue":"3","key":"key\n\t\t\t\t20180420105421_CIT0022","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"key\n\t\t\t\t20180420105421_CIT0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"key\n\t\t\t\t20180420105421_CIT0024","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20180420105421_CIT0025","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"key\n\t\t\t\t20180420105421_CIT0026","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1470-2045(11)70406-5","article-title":"Phase 2 trial design in neuro-oncology revisited: a report from the RANO group","volume":"13","author":"Galanis","year":"2012","journal-title":"Lancet Oncol"},{"issue":"21","key":"key\n\t\t\t\t20180420105421_CIT0027","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1158\/1078-0432.CCR-12-1841","article-title":"Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03","volume":"18","author":"Lee","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"15","key":"key\n\t\t\t\t20180420105421_CIT0028","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"key\n\t\t\t\t20180420105421_CIT0029","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20180420105421_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20180420105421_CIT0031","unstructured":"Loboda A , FantinVR, RandolphSet al Vorinostat (suberoylanilide hydroxamic acid, SAHA) induces robust gene expression changes in peripheral blood mononuclear cells from patients with solid tumors, consistent with its effect in panels of human tumor cell lines. Paper presented at: AACR2007."},{"key":"key\n\t\t\t\t20180420105421_CIT0032","doi-asserted-by":"crossref","unstructured":"Loboda A , FantinVR, RandolphSet al Identification of informative gene expression signatures indicative of vorinostat (suberoylanilide hyroxamic acid, SAHA) exposure and clinical efficacy in patients with advanced cutaneous T-cell lymphoma. Paper presented at: AACR2007.","DOI":"10.1182\/blood.V108.11.4686.4686"},{"issue":"26","key":"key\n\t\t\t\t20180420105421_CIT0033","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"key\n\t\t\t\t20180420105421_CIT0034","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1093\/nar\/gkq622","article-title":"MapSplice: accurate mapping of RNA-seq reads for splice junction discovery","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180420105421_CIT0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"30","key":"key\n\t\t\t\t20180420105421_CIT0036","doi-asserted-by":"crossref","first-page":"30295","DOI":"10.18632\/oncotarget.4497","article-title":"IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas","volume":"6","author":"Leeper","year":"2015","journal-title":"Oncotarget"},{"issue":"25","key":"key\n\t\t\t\t20180420105421_CIT0037","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2015.61.5005","article-title":"Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial","volume":"33","author":"Sandmann","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180420105421_CIT0038","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1038\/cddis.2014.412","article-title":"Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe","volume":"5","author":"Cornago","year":"2014","journal-title":"Cell Death Dis"},{"issue":"2","key":"key\n\t\t\t\t20180420105421_CIT0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.2014-0418","article-title":"Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme","volume":"20","author":"van Linde","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"key\n\t\t\t\t20180420105421_CIT0040","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/auto.28984","article-title":"A phase I\/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme","volume":"10","author":"Rosenfeld","year":"2014","journal-title":"Autophagy"},{"issue":"5","key":"key\n\t\t\t\t20180420105421_CIT0041","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro Oncol"},{"issue":"10","key":"key\n\t\t\t\t20180420105421_CIT0042","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2 Pt B","key":"key\n\t\t\t\t20180420105421_CIT0043","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.canlet.2014.09.049","article-title":"DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells","volume":"356","author":"Pont","year":"2015","journal-title":"Cancer Lett"},{"issue":"12","key":"key\n\t\t\t\t20180420105421_CIT0044","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1582-4934.2011.01296.x","article-title":"Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic","volume":"15","author":"Shabason","year":"2011","journal-title":"J Cell Mol Med"},{"issue":"7","key":"key\n\t\t\t\t20180420105421_CIT0045","first-page":"2407","article-title":"Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors","volume":"32","author":"Asklund","year":"2012","journal-title":"Anticancer Res"},{"issue":"3","key":"key\n\t\t\t\t20180420105421_CIT0046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/cbt.27309","article-title":"HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells","volume":"15","author":"Booth","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"key\n\t\t\t\t20180420105421_CIT0047","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"key\n\t\t\t\t20180420105421_CIT0048","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol"},{"issue":"24","key":"key\n\t\t\t\t20180420105421_CIT0049","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2217\/fon.15.258","article-title":"What next for newly diagnosed glioblastoma","volume":"11","author":"Domingo-Musibay","year":"2015","journal-title":"Future Oncol"},{"issue":"23","key":"key\n\t\t\t\t20180420105421_CIT0050","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"key\n\t\t\t\t20180420105421_CIT0051","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"key\n\t\t\t\t20180420105421_CIT0052","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/20\/4\/546\/24687974\/nox161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:17:25Z","timestamp":1602789445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/20\/4\/546\/4091090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,8,22]]},"published-print":{"date-parts":[[2018,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nox161","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2017,8,22]]}}}